Screener
Xeris Biopharma Holdings, Inc. XERS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s retained earnings?
- Xeris Biopharma Holdings, Inc. (XERS) reported retained earnings of -$700.17M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s retained earnings changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s retained earnings decreased by 2.5% year-over-year, from -$683.01M to -$700.17M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s retained earnings has grown at a 14.8% compound annual growth rate (CAGR), from -$337.39M to -$671.31M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Xeris Biopharma Holdings, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude